摘要
目的比较子宫内膜异位症(EMT)患者与健康女性的经血源间充质干细胞(MenSCs)的自噬功能。方法分别从EMT患者及健康女性的月经血中提取EMT MenSCs(E-MenSCs)和正常MenSCs(H-MenSCs),并借助成脂、成骨诱导分化鉴定其干细胞属性。通过CCK-8法比较E-MenSCs和H-MenSCs在12、24、48、72、96、120 h时刻于波长450 nm的吸光度(A)值,并绘制细胞增殖曲线,比较2组细胞的细胞活力;运用透射电镜观察E-MenSCs与H-MenSCs的细胞形态,检测比较其中自噬体和自噬溶酶体的数量;采用Western blotting法检测E-MenSCs和H-MenSCs中自噬标志物微管相关蛋白轻链3-II(LC3-II)和Beclin1的蛋白表达。结果E-MenSCs和H-MenSCs均为长梭形,呈辐射状扩散,且经成脂、成骨诱导分化后均有脂滴、钙结节形成。与H-MenSCs比较,E-MenSCs在72、96、120 h的细胞活力均显著升高(P<0.01、0.001),自噬体和自噬溶酶体数量显著减少(P<0.05、0.01),且LC3-Ⅱ、Beclin1蛋白表达量也显著降低(P<0.05)。结论与H-MenSCs比较,E-MenSCs的自噬功能减弱,这可能是EMT发病进展的潜在机制。
Objective To compare the autophagy of menstrual blood-derived mesenchymal stem cells(MenSCs)in patients with endometriosis(EMT)and healthy women.Methods EMT MenSCs(E-MenSCs)and healthy MenSCs(H-MenSCs)were isolated from the menstrual blood of patients with endometriosis and healthy volunteers,respectively.Then their stem cell properties were identified using adipogenic and osteogenic differentiation.The absorbance(A)value at 450 nm of E-MenSCs and H-MenSCs at 12,24,48,72,96,and 120 h time points were obtained using CCK-8 assay,the cell proliferation curves were plotted,and the cell viability of E-MenSCs and H-MenSCs were compared.The cell morphology of E-MenSCs and H-MenSCs was observed by transmission electron microscope,and the number of autophagosome and autophagic lysosome was detected and compared.The expression of autophagy marker proteins(LC3-II and Beclin1)in E-MenSCs and H-MenSCs were detected by Western blotting.Results E-MenSCs and H-MenSCs,long spindle-shaped,diffused radially.After adipogenic and osteogenic differentiation,the lipid droplets and calcium nodules in E-MenSCs and H-MenSCs were observed.In contrast to H-MenSCs,E-MenSCs showed increased cell viability at 72,96,and 120 h(P<0.01 and 0.001),decreased expressions of autophagosomes and autolysosomes(P<0.05 and 0.01),and reduced LC3-II and Beclin1 proteins(P<0.05).Conclusion E-MenSCs autophagy is weakened compared with H-MenSCs,which might be the underlying mechanism of EMT pathogenesis and progression.
作者
张悦健
林陶秀
何甜甜
杨思晨
李长香
睢丛璐
郭亚楠
马小娜
ZHANG Yuejian;LIN Taoxiu;HE Tiantian;YANG Sichen;LI Changxiang;SUI Conglu;GUO Ya'nan;MA Xiaona(The Third School of Clinical Medicine,Beijing University of Chinese Medicine,Beijing 100029,China;School of Traditional Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100029,China;Beijing University of Chinese Medicine Third Affiliated Hospital,Beijing 100029,China)
出处
《药物评价研究》
CAS
2023年第7期1417-1423,共7页
Drug Evaluation Research
基金
国家自然科学基金面上项目(81973895)
北京中医药大学重点攻关项目(2020-JYB-ZDGG-143-3)。